NASDAQ:SXTC China SXT Pharmaceuticals (SXTC) Stock Price, News & Analysis $2.52 -0.05 (-1.95%) Closing price 04:00 PM EasternExtended Trading$2.54 +0.02 (+0.83%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About China SXT Pharmaceuticals Stock (NASDAQ:SXTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SXTC alerts:Sign Up Key Stats Today's Range$2.52▼$2.7450-Day Range$1.93▼$214.4052-Week Range$1.78▼$83,758.80Volume39,377 shsAverage Volume796,246 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview China SXT Pharmaceuticals, Inc. is a China-based pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine products. The company’s offerings are designed for use in traditional medicine and health care applications and are marketed primarily in China. Its product portfolio includes traditional Chinese medicine decoction pieces, finished traditional Chinese medicines and health care products. These products are sold through distribution and retail channels serving pharmacies, medical institutions and other health care-related customers. The company has also described its products as including prescription medicines, over-the-counter medicines and dietary or health supplements. China SXT Pharmaceuticals is based in Taizhou, Jiangsu Province, China, and has historically operated manufacturing facilities in the region. The company completed its initial public offering on the Nasdaq under the symbol SXTC in 2019. Its business remains centered on traditional Chinese medicine production and distribution within the Chinese market.AI Generated. May Contain Errors. Read More China SXT Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreSXTC MarketRank™: China SXT Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingChina SXT Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageChina SXT Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about China SXT Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioChina SXT Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.27% of the float of China SXT Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverChina SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in China SXT Pharmaceuticals has recently increased by 251.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChina SXT Pharmaceuticals does not currently pay a dividend.Dividend GrowthChina SXT Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.60 News SentimentChina SXT Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for China SXT Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SXTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, China SXT Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.95% of the stock of China SXT Pharmaceuticals is held by insiders.Percentage Held by Institutions5.02% of the stock of China SXT Pharmaceuticals is held by institutions.Read more about China SXT Pharmaceuticals' insider trading history. Receive SXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China SXT Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTC Stock News HeadlinesChina SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest UpdateSeptember 26 at 5:21 AM | americanbankingnews.comChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationAugust 5, 2026 | globenewswire.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 28 at 1:00 AM | Paradigm Press (Ad)Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)July 24, 2026 | globenewswire.comChina SXT Pharmaceuticals Raises $9 Million in Registered Direct OfferingJuly 24, 2026 | tipranks.comChina SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional InvestorsJuly 23, 2026 | quiverquant.comQChina SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct OfferingJuly 23, 2026 | globenewswire.comChina SXT Pharmaceuticals Inc. Cl AJuly 14, 2026 | barrons.comSee More Headlines SXTC Stock Analysis - Frequently Asked Questions How have SXTC shares performed this year? China SXT Pharmaceuticals' stock was trading at $19,200.00 at the start of the year. Since then, SXTC shares have decreased by 100.0% and is now trading at $2.52. How were China SXT Pharmaceuticals' earnings last quarter? China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) released its quarterly earnings results on Wednesday, July, 1st. The company reported $6.84 EPS for the quarter. The business earned $0.26 million during the quarter. When did China SXT Pharmaceuticals' stock split? China SXT Pharmaceuticals shares reverse split on the morning of Tuesday, February 25th 2025.The 1-8 reverse split was announced on Friday, February 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did China SXT Pharmaceuticals IPO? China SXT Pharmaceuticals (SXTC) raised $15 million in an initial public offering on Friday, January 4th 2019. The company issued 3,750,000 shares at a price of $4.00 per share. How do I buy shares of China SXT Pharmaceuticals? Shares of SXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of China SXT Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that China SXT Pharmaceuticals investors own include MARA (MARA), NIO (NIO), Meta Platforms (META), Alibaba Group (BABA), JD.com (JD) and Blink Charging (BLNK). Company Calendar Last Earnings7/01/2026Today9/28/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SXTC's financial health is in the Red zone, according to TradeSmith. SXTC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SXTC CIK1723980 Webwww.sxtchina.com Phone8652386299087FaxN/AEmployees56Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio7.94 Quick Ratio7.76 Sales & Book Value Annual Sales$1.14 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2,468.59 per share Price / Book0.00Miscellaneous Outstanding Shares480,000Free Float459,000Market Cap$1.21 million OptionableNot Optionable Beta1.85 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SXTC) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
